CoChat

Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs

Peyrot, Mark, Rubin, Richard R., Polonsky, William H., Jennie Best, H. · 2010 · Current Medical Research and Opinion

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To determine whether treatment satisfaction and quality of life were affected by adding mealtime pramlintide or rapid-acting insulin analogs (RAIAs) to basal insulin therapy for patients with inadequately controlled type 2 diabetes. RESEARCH DESIGN AND METHODS: In this 24-week open-label, multicenter study of adults with type 2 diabetes, mealtime pramlintide (PRAM) (120 microg fixed dose; n = 56) or titrated RAIAs (n = 56) was added to basal insulin therapy with or without oral antidiabetic medications. CLINICAL TRIAL REGISTRATION: ClinicalTrials.Gov NCT00467649. MAIN OUTCOME MEASURES: Quality of life (Diabetes Distress Scale - DDS, and Pittsburgh Sleep Quality Index - PSQI), and treatment satisfaction (Diabetes Treatment Satisfaction Questionnaire - DTSQ, and Pramlintide Treatment Satisfaction Questionnaire - PRAM-TSQ) were assessed at baseline and week 24. Mixed-effect models estimated mean group changes from baseline to week 24 (adjusted for baseline scores) in patient reported outcomes. RESULTS: PRAM patients experienced significant improvement in total diabetes distress, while RAIA patients did not; both groups experienced significant improvement in regimen-related distress and physician-related distress. Between-group differences in DDS measures were not significant. PRAM patients experienced significant improvement in sleep latency and daytime dysfunction, while RAIA patients did not; the difference between groups was significant for daytime dysfunction. Both treatment groups experienced significant improvement in most individual DTSQ items and total diabetes treatment satisfaction, while only PRAM patients experienced significant improvement in perceived hypoglycemia. Between-group differences in DTSQ measures were not significant. Both treatment groups experienced significant improvement in most individual PRAM-TSQ items and total treatment satisfaction; RAIA patients experienced increased eating flexibility and reduced perceived weight control. PRAM patients experienced significantly better perceived weight and appetite control than RAIA patients. LIMITATIONS: The sample size was relatively small and there were few non-white subjects. The schedule for implementation of change in therapy may have affected study outcomes. CONCLUSIONS: Adding pramlintide on a background of basal insulin improved some aspects of treatment satisfaction and quality of life relative to adding rapid-acting insulin analogs.

Overview

Integrity signals

Registry

Crossref · 10.1185/03007991003634759

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 22 references

Research works printed but not linked: 2

  1. Bradley C. The Diabetes Treatment Satisfaction Questionnaire: DTSQ. In Handbook of Psychology and Diabetes: a Guide to Psychological Measurement in Diabetes Research and Practice. Chur, Switzerland: Harwood Academic Publishers, 1994:111-32
  2. Peyrot M, Rubin RR, Polonsky WH, et al. Clinical and patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin. Meeting abstract. Diabetes 2009;58(Suppl 1):A474

Cited by

See all 27

Metadata

Authors
Peyrot, M., Rubin, R. R., Polonsky, W. H., & Jennie Best, H.
Affiliations
  • Johns Hopkins University (US)
  • University of California San Diego (US)
  • Amylin Pharmaceuticals, Inc., San Diego, CA, USA
Corresponding author
Peyrot, Mark
Venue
Current Medical Research and Opinion
Published
2010-03-03
Volume
26
Issue
5
Pages
1047-1054
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W2168442288
Cited by
27
References
22
Citations by year
2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 3 · 2015: 4 · 2014: 3 · 2013: 5 · 2012: 3
FWCI
2.17
Type
journal article
Language
en
Open access
closed
Locations
  • Current Medical Research and Opinion (publishedVersion)
  • PubMed (publishedVersion)
Funders
Amylin Pharmaceuticals
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, pramlintide, rapid-acting insulin analogs, basal insulin, mealtime insulin, treatment satisfaction, quality of life, diabetes distress, sleep quality, hypoglycemia, weight management, appetite regulation
MeSH terms
Adult, Amyloid, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Quality of Life, Patient Satisfaction, Islet Amyloid Polypeptide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs. https://app.cochat.ai/papers/10.1185/03007991003634759
The paper
Peyrot, M., Rubin, R. R., Polonsky, W. H., & Jennie Best, H. (2010). Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs. Current Medical Research and Opinion. https://doi.org/10.1185/03007991003634759

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.